Bellecapital International Ltd. raised its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 41.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 46,123 shares of the biopharmaceutical company’s stock after acquiring an additional 13,491 shares during the period. Bellecapital International Ltd.’s holdings in Pfizer were worth $1,328,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Moneta Group Investment Advisors LLC increased its stake in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter worth $3,150,472,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley increased its stake in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after purchasing an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Pfizer during the first quarter worth $311,238,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Pfizer Price Performance
Pfizer stock opened at $27.75 on Monday. The stock has a market cap of $157.14 billion, a price-to-earnings ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The firm has a 50-day moving average of $27.44 and a two-hundred day moving average of $29.37.
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the business posted $1.14 EPS. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on PFE. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. UBS Group reduced their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Truist Financial reduced their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $36.88.
View Our Latest Analysis on Pfizer
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.